KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查 入排置信度 0.98

A randomized, observer-blind, controlled phase III clinical trial assessing safety and immunological non-inferiority of Vi-diphtheria toxoid versus Vi-tetanus toxoid typhoid conjugate vaccine in healthy volunteers in eastern Nepal.

Shipra Chaudhary, Gauri Shankar Shah, Nisha Keshary Bhatta, Prakash Poudel, Basant Rai, Surendra Uranw, Prashant Mani Tripathi, Basudha Khanal, Anup Ghimire, Nikita Rai, Birendra Prasad Gupta, Sridhar Vemula, T Anh Wartel, Sushant Sahastrabuddhe, Tarun Saluja

Hum Vaccin Immunother 19(1) 2203634

PMID37128723
PMCIDPMC10142305
DOI10.1080/21645515.2023.2203634
发表日期2023-05-02
入排依据:未发现恶性肿瘤人群证据。
摘要

摘要

Typhoid remains one of the major serious health concerns for children in developing countries. With extremely drug-resistant cases emerging, preventative measures like sanitation and vaccination, including typhoid conjugate vaccines (TCV) remain the mainstay in its prevention and control. Different types of TCVs are being developed to meet the global demand. This report outlines the results from a study done to assess the immunogenicity and safety of Vi-Diphtheria toxoid (Vi-DT) TCV in Nepal. The study was a randomized, active-controlled, immunological non-inferiority and safety study. Eligible participants from Sunsari and Morang districts of eastern Nepal were randomized into 4 study groups (A-D) within 3 age strata (6 months to <2 years, 2 to <18 years, and 18 to 45 years). Groups A to C received a single dose (25 μg) of Vi-DT test vaccine from any of the 3 lots, while group D received the comparator, Typbar-TCV®, Vi-tetanus toxoid (Vi-TT) vaccine (25 μg) in 1:1:1:1 ratio and evaluated at 4 weeks postvaccination with 6 months follow-up. Amongst 400 randomized participants, anti-Vi-IgG seroconversion rates for all age strata in Vi-DT pooled groups (A+B+C) were 100.00% (97.5% CI 98.34-100.00) vs 98.99% (97.5% CI 93.99-99.85) in Vi-TT group (D) at 4 weeks. Comparable safety events were reported between the groups. Three serious adverse events (1 in Vi-DT; 2 in Vi-TT group) were reported during the 6 months follow-up, none being related to the investigational product. Thus, Vi-DT vaccine is safe, immunogenic, and immunologically non-inferior to Vi-TT when analyzed at 4 weeks postvaccination.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。